Patents by Inventor Philip M. Sass

Philip M. Sass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080318321
    Abstract: Bacteria are manipulated to create desirable output traits using dominant negative alleles of mismatch repair proteins. Enhanced hypermutation is achieved by combination of mismatch repair deficiency and exogenously applied mutagens. Stable bacteria containing desirable output traits are obtained by restoring mismatch repair activity to the bacteria.
    Type: Application
    Filed: October 31, 2007
    Publication date: December 25, 2008
    Applicants: The Johns Hopkins University, Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Bert Vogelstein, Kenneth W. Kinzler
  • Publication number: 20080292641
    Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.
    Type: Application
    Filed: February 8, 2007
    Publication date: November 27, 2008
    Applicant: Morphotek, Inc.
    Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
  • Publication number: 20080248034
    Abstract: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
    Type: Application
    Filed: April 4, 2008
    Publication date: October 9, 2008
    Inventors: Yuhong Zhou, Brian Tomkowicz, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Publication number: 20080182242
    Abstract: Dominant-negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into mammalian cells new cell lines with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation or introduction of mutations by chemical mutagens. These methods are useful for generating novel and highly active antimicrobial molecules as well as superior antimicrobial agents from pre-existing chemicals. These methods are also useful for generating cell lines expressing novel antimicrobials that are useful for pharmaceutical manufacturing.
    Type: Application
    Filed: April 18, 2007
    Publication date: July 31, 2008
    Applicant: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
  • Publication number: 20080176329
    Abstract: Yeast cells are mutagenized to obtain desirable mutants. Mutagenesis is mediated by a defective mismatch repair system which can be enhanced using conventional exogenously applied mutagens. Yeast cells with the defective mismatch repair system are hypermutable, but after selection of desired mutant yeast strains, they can be rendered genetically stable by restoring the mismatch repair system to proper functionality.
    Type: Application
    Filed: October 31, 2007
    Publication date: July 24, 2008
    Applicants: The Johns Hopkins University, Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Bert Vogelstein, Kenneth W. Kinzler
  • Publication number: 20080131427
    Abstract: Whole Genome Evolution Technology can be considered a broad tool for supporting the needs for scaleable manufacturing of therapeutic antibodies. Its random nature and in vivo mode of action separate this process from other complementary technologies, thus providing alternative solutions to improve a host cell's manufacturing performance. The speed with which a pre-existing production strain can be optimized makes this process suitable for satisfying the current need for rapid cell line optimization to produce faster growing cells exhibiting high titers of antibody at the preclinical, clinical or commercialization stage.
    Type: Application
    Filed: April 16, 2007
    Publication date: June 5, 2008
    Applicant: Morphotek, Inc.
    Inventors: J. Bradford Kline, Qimin Chao, Philip M. Sass, Luigi Grasso, Nicholas C. Nicolaides
  • Publication number: 20080124744
    Abstract: Antibodies against PMS2 and PMS2-134 and cells that produce the anti-PMS2 and anti-PMS2-134 antibodies are provided. The antibodies of the invention may be used in methods for detecting a PMS2 protein, including a truncated PMS2, and in methods for detecting an abnormal condition in a patient.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 29, 2008
    Applicant: Morphotek, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass, Eric Routhier
  • Patent number: 7332584
    Abstract: Antibodies against PMS2 and PMS2-134 and cells that produce the anti-PMS2 and anti-PMS2-134 antibodies are provided. The antibodies of the invention may be used in methods for detecting a PMS2 protein, including a truncated PMS2, and in methods for detecting an abnormal condition in a patient.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: February 19, 2008
    Assignee: Morphotek, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass, Eric Routhier
  • Patent number: 7319036
    Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. The enhanced rate of mutation can be further augmented using mutagens. Moreover, the hypermutability of mismatch repair deficient cells can be remedied to stabilize cells or mammals with useful mutations.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: January 15, 2008
    Assignees: The Johns Hopkins University School of Medicine, Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Bert Vogelstein, Kenneth W. Kinzler
  • Patent number: 7235643
    Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the affinity of monoclonal antibodies and monoclonal antibodies with increased affinity.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: June 26, 2007
    Assignee: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
  • Patent number: 7223598
    Abstract: Dominant-negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into mammalian cells new cell lines with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation or introduction of mutations by chemical mutagens. These methods are useful for generating novel and highly active antimicrobial molecules as well as superior antimicrobial agents from pre-existing chemicals. These methods are also useful for generating cell lines expressing novel antimicrobials that are useful for pharmaceutical manufacturing.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: May 29, 2007
    Assignee: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
  • Patent number: 7026119
    Abstract: Bacteria are manipulated to create desirable output traits using dominant negative alleles of mismatch repair proteins. Enhanced hypermutation is achieved by combination of mismatch repair deficiency and exogenously applied mutagens. Stable bacteria containing desirable output traits are obtained by restoring mismatch repair activity to the bacteria.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: April 11, 2006
    Assignees: Morphotek, Inc., The Johns Hopkins University
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Bert Vogelstein, Kenneth W. Kinzler
  • Patent number: 6982169
    Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. Methods of generating mutations in genes of interest and of making various cells mismatch repair defective through the use of chemicals to block mismatch repair in in vivo are disclosed.
    Type: Grant
    Filed: January 15, 2001
    Date of Patent: January 3, 2006
    Assignee: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
  • Patent number: 6921666
    Abstract: Yeast cells are mutagenized to obtain desirable mutants. Mutagenesis is mediated by a defective mismatch repair system which can be enhanced using conventional exogenously applied mutagens. Yeast cells with the defective mismatch repair system are hypermutable, but after selection of desired mutant yeast strains, they can be rendered genetically stable by restoring the mismatch repair system to proper functionality.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: July 26, 2005
    Assignees: The Johns Hopkins University, Morphotek
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Bert Vogelstein, Kenneth W. Kinzler
  • Patent number: 6825038
    Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. The enhanced rate of mutation can be further augmented using mutagens. Moreover, the hypermutability of mismatch repair deficient cells can be remedied to stabilize cells or mammals with useful mutations.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: November 30, 2004
    Assignees: The Johns Hopkins University, Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Philip M. Sass, Luigi Grasso, Bert Vogelstein, Kenneth W. Kinzler
  • Publication number: 20040235108
    Abstract: Monoclonal antibodies that specifically bind to the tetrameric form of the alpha-folate receptor and not the monomeric form are provided. The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-&agr;”), such as ovarian cancer. Hybridoma cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of detecting and treating cancer using the antibodies, derivatives and fragments also are provided.
    Type: Application
    Filed: May 21, 2004
    Publication date: November 25, 2004
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Publication number: 20040237125
    Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production.
    Type: Application
    Filed: May 19, 2004
    Publication date: November 25, 2004
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
  • Publication number: 20040214288
    Abstract: The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinity antibodies may be mismatch repair defective due to defects of endogenous mismatch repair subunits of through expression of a dominant negative allele of a mismatch repair gene which allows the hybridoma cell to be hypermutable, may be rendered hypermutable by chemical means, or may be naturally mismatch repair deficient. High-affinity antibodies and high titer producer cells producing antibodies may be prepared by the methods of the invention.
    Type: Application
    Filed: November 14, 2003
    Publication date: October 28, 2004
    Inventors: Luigi Grasso, Shaohong Liang, Nicholas C. Nicolaides, Philip M. Sass
  • Patent number: 6808894
    Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: October 26, 2004
    Assignee: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass
  • Publication number: 20040158886
    Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within genes encoding for therapeutic antigens to produce altered polypeptides with enhanced antigenic and immunogenic activity. Moreover, these methods are useful for generating effective vaccines.
    Type: Application
    Filed: March 30, 2004
    Publication date: August 12, 2004
    Applicant: Morphotek, Inc.
    Inventors: Nicholas C. Nicolaides, Luigi Grasso, Philip M. Sass